v3.25.3

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 44,320	$ 13,886
Restricted cash and cash equivalents	100	100
Prepaid expenses and other current assets	4,631	2,341
Total current assets	49,051	16,327
Operating lease right-of-use assets	556	925
Goodwill	1,914	1,914
Deposits and other assets	34	266
Total assets	51,555	19,432
Current liabilities:
Accounts payable	2,305	3,500
Accrued expenses and other current liabilities	3,021	5,466
Operating lease liabilities	599	544
Total current liabilities	5,925	9,510
Operating lease liabilities, non-current	0	457
Total liabilities	5,925	9,967
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.0001 par value; 350,000,000 shares authorized, 125,078,525 and 73,977,459 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	12	7
Additional paid-in capital	312,948	257,583
Accumulated deficit	(267,330)	(248,125)
Total stockholders’ equity	45,630	9,465
Total liabilities and stockholders’ equity	$ 51,555	$ 19,432

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

SELLAS Life Sciences Group, Inc. 10-Q